Chemical industry – Page 66
-
BusinessDanaher boosts diagnostics with Cepheid buyout
$4bn deal strengthens Danaher’s life sciences portfolio
-
BusinessFDA’s first Duchenne drug approval reveals schism
Oligonucleotide drug reaches market amid pressure from patient families and strife over ‘patient-focused drug development’ at the regulator
-
BusinessFertiliser firms Agrium and PotashCorp to merge
Canadian combination will create one of the largest crop nutrient companies in the world.
-
BusinessBayer to buy seed giant Monsanto
$66bn deal follows agrochemical consolidation trend, but could threaten competition and hit R&D
-
BusinessAtanor chemical plant in Argentina shuttered
Toxic releases have led to the indefinite closure of the facility after a decade-long legal fight
-
BusinessBrexit could push Japanese pharma out of the UK
Warnings that Japanese R&D investment in the UK is endangered by plans to leave the EU
-
-
BusinessSadara cracker eyes richer chemical rewards
Joint venture between Dow and Saudi Aramco will target added value plastics and speciality chemicals
-
BusinessHealthcare firms invest in Crispr gene editing technology
Crispr licence agreements open up opportunities in drug discovery
-
BusinessNovartis reshuffle puts 120 staff at risk
Commitment to gene and cell therapy treatments emphasised as unit broken up amid pharmaceutical division refocus
-
BusinessUS government agency awards Monsanto whistleblower $22 million
Pay-out is second largest reward from US whistleblower programme
-
-
BusinessJoined-up thinking
The rift between contract medicinal chemistry and chemical development needs to be bridged
-
OpinionDon’t fear the Crispr
Does simple gene-editing mean the end of traditional medicinal chemistry? Probably not
-
BusinessFatal incidents at two chemical plants
In recent weeks three people have been killed in chemical plant accidents in Malaysia and the US
-
BusinessFDA urges labs to test all blood donations for Zika
Agency has also given emergency authorisation to two new Zika blood tests
-
BusinessPfizer to buy Astrazeneca’s antibiotics
Deal tops up Pfizer’s late-stage development pipeline, but AZ will retain biological programmes
-
BusinessPfizer gambles on $14bn Medivation deal
Cancer specialist likely just one target in hunt for marketed drugs to offset patent expiries
-
ResearchMembranes promise to slash energy needed to separate hydrocarbons
ExxonMobil-backed study allows reverse osmosis of hard-to-distinguish para-xylene and ortho-xylene
-
BusinessEU examines Dow–DuPont union
European commission probes competition implications of the planned mega-merger